gene_symbol
FCGR2A
hgnc_id
HGNC:3616
binding_type
receptor ligand recognition
cytotoxicity
NO
cytotoxicity_type
INDIRECT
cytotoxicity_mechanism
Dinutuximab binds GD2 on tumor cells and engages Fcγ receptors (including CD32a) on immune effector cells to mediate ADCC/ADCP and complement-dependent cytotoxicity against GD2+ cells; CD32a+ cells themselves are not targeted or killed.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Myeloid Fc receptor mediating ADCP/ADCC via IgG1 Fc
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06450041
disease_id_num_tar_ref
1626
drug_id_num_tar_ref
4400